Cargando…

The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials

BACKGROUND: Glucocorticoid-induced osteoporosis (GIOP) is the most common secondary osteoporosis, alendronate (ALE) and teriparatide (TPTD) are widely used in the treatment of GIOP. However, which of these two drugs has a better curative effect needs the support of evidence-based medicine. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhi-Ming, Zhang, Min, Zong, Yuan, Zhang, Ding, Shen, Zhu-Bin, Guan, Xiao-Qing, Yin, Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154179/ https://www.ncbi.nlm.nih.gov/pubmed/35639783 http://dx.doi.org/10.1371/journal.pone.0267706

Ejemplares similares

Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials
por: Wang, Ya-Kang, et al.
Publicado: (2017)

An effect comparison of alendronate and teriparatide in patients with glucocorticoid-induced osteoporosis: A protocol for systematic review and meta-analysis
por: Liang, Na, et al.
Publicado: (2022)

Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
por: Li, Mei, et al.
Publicado: (2022)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Management of glucocorticoids-induced osteoporosis: role of teriparatide
por: Migliaccio, Silvia, et al.
Publicado: (2009)

Role of teriparatide in treatment of glucocorticoid-induced osteoporosis
por: Lau, Arthur N, et al.
Publicado: (2010)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide
por: Mori, Takahiro, et al.
Publicado: (2019)

Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases: A meta-analysis
por: Kan, Shun-Li, et al.
Publicado: (2016)

Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study
por: Yang, Dazhi, et al.
Publicado: (2023)

Effects of alendronate for treatment of glucocorticoid-induced osteoporosis: A meta-analysis of randomized controlled trials
por: Wang, Ya-Kang, et al.
Publicado: (2018)

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020)

Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis
por: Dore, Robin K
Publicado: (2013)

Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis
por: Kim, Yeesuk, et al.
Publicado: (2020)

Teriparatide vs. Alendronate as a treatment for osteoporosis: Changes in biochemical markers of bone turnover, BMD and quality of life
por: Panico, Annalisa, et al.
Publicado: (2011)

Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05
por: Mori, Satoshi, et al.
Publicado: (2022)

Update on the safety and efficacy of teriparatide in the treatment of osteoporosis
por: Minisola, Salvatore, et al.
Publicado: (2019)

Teriparatide in the management of osteoporosis
por: Bodenner, Donald, et al.
Publicado: (2007)

Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
por: Seno, Takahiro, et al.
Publicado: (2016)

Promotion effect of extracts from plastrum testudinis on alendronate against glucocorticoid-induced osteoporosis in rat spine
por: Ren, Hui, et al.
Publicado: (2017)

Teriparatide – Indications beyond osteoporosis
por: Cheng, Marilyn Lee, et al.
Publicado: (2012)

Therapy of Osteoporosis in Men with Teriparatide
por: Cusano, Natalie E., et al.
Publicado: (2011)

The Carcinogenicity of Alendronate in Patients with Osteoporosis: Evidence from Cohort Studies
por: Chen, Ling-Xiao, et al.
Publicado: (2015)

Meta-regression analysis of the efficacy of alendronate for prevention of glucocorticoid-induced fractures
por: Qiu, Mei, et al.
Publicado: (2020)

Alendronate Sodium in the Management of Osteoporosis
por: Prinsloo, P J J, et al.
Publicado: (2006)

Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus
por: Xiong, Zhencheng, et al.
Publicado: (2022)

A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05
por: Hagino, H., et al.
Publicado: (2021)

Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan
por: Mori, Takahiro, et al.
Publicado: (2021)

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden
por: Murphy, Daniel R, et al.
Publicado: (2012)

Profile of teriparatide in the management of postmenopausal osteoporosis
por: Sikon, Andrea, et al.
Publicado: (2010)

Teriparatide for osteoporosis: importance of the full course
por: Lindsay, R., et al.
Publicado: (2016)

Treatment of osteoporosis with teriparatide: The Slovenian experience
por: Kocjan, Tomaz, et al.
Publicado: (2021)

Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
por: Yuan, Chuanjian, et al.
Publicado: (2023)

The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial
por: Iseri, Ken, et al.
Publicado: (2018)

Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax(®)) for osteoporosis treatment
por: Unnanuntana, Aasis, et al.
Publicado: (2017)

Comparative Effects of Teriparatide and Risedronate in Glucocorticoid-Induced Osteoporosis in Men: 18-Month Results of the EuroGIOPs Trial
por: Glüer, Claus-C, et al.
Publicado: (2013)

Efficacy of teriparatide in the treatment of nontraumatic osteonecrosis of the femoral head: a retrospective comparative study with alendronate
por: Arai, Ryuta, et al.
Publicado: (2017)

A Case of Teriparatide on Pregnancy-Induced Osteoporosis
por: Lee, Seok Hong, et al.
Publicado: (2013)

Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials
por: Liu, Zhiming, et al.
Publicado: (2020)

Effects of teriparatide in Chinese and Caucasian women with osteoporosis: bridging study on efficacy
por: Xie, Zhongjian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s0c5jgvqvg026uhn8e9n1img0i